Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:58:05.294Z.
Calculation as of: 2026-10-06T19:58:05.294Z.
Quote observation: 2026-10-06T19:55:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$212.65M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.94M
EV/Sales Ratio
6551.55x
TTM Avg
8843.11x
3Y Avg
4911.03x
5Y Avg
2972.75x
Market Cap
$212.25M
EV/Sales Ratio
1.15x
TTM Avg
2.73x
3Y Avg
3.49x
5Y Avg
2.89x
Market Cap
$215.58M
EV/Sales Ratio
9.23x
TTM Avg
17.85x
3Y Avg
16.79x
5Y Avg
16.79x
Market Cap
$209.68M
EV/Sales Ratio
33.92x
TTM Avg
25.48x
3Y Avg
10.85x
5Y Avg
10.86x
Market Cap
$217.50M
EV/Sales Ratio
N/A
TTM Avg
0.28x
3Y Avg
11342.46x
5Y Avg
7406.39x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $212.65M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | 6551.55x | 8843.11x | 4911.03x | 2972.75x |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 1.15x | 2.73x | 3.49x | 2.89x |
| Sionna Therapeutics, Inc. (SION)vs › | $211.53M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | 2.74x | 9.07x | 6.60x | 11.04x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.58M | 9.23x | 17.85x | 16.79x | 16.79x |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.68M | 33.92x | 25.48x | 10.85x | 10.86x |
| Pro-Dex, Inc. (PDEX)vs › | $208.44M | 2.82x | 2.41x | 2.22x | 2.09x |
| Keros Therapeutics, Inc. (KROS)vs › | $217.50M | N/A | 0.28x | 11342.46x | 7406.39x |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
